Anti-epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region - Global Industry Insights, Trends, and Forecast, 2017-25

  • Published On : Sep 2017 |
  • Pages : 200 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Anti-Epileptic Drugs for Pediatrics

Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

Newer drug therapies with symptom specific indications are expected to boost market growth

Epilepsy is a highly prevalent disorder, especially in emerging economies as an estimated 50 million people worldwide are suffering with epilepsy out of which almost 80% live in emerging economies as per the World Health Organization (WHO). According to the American Academy of Pediatrics, as of April 2017, epilepsy is estimated to affect 0.5% to 1% of children globally and is the most prevalent chronic condition of the central nervous system among children. According to Epilepsy Foundation, each year, around 150,000 new cases of epilepsy are reported in the U.S. and the rate of occurrence is high among young children and geriatric population. Furthermore, the Society of Neuroscience, in 2015, stated that epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varies significantly. The incidence and prevalence of epilepsy for children appears to be lower in developed economies and highest in rural areas of emerging economies. This is mainly attributed to the presence of FDA-approved anti-epileptic drugs in the developed economies and the vast distribution channel providing higher accessibility. Scientific and technological advances have introduced many new medications in the past decade, which are used in combination and in a personalized way by physicians for the treatment of pediatrics. The U.S. Food & Drug Administration (FDA) approved drugs, including Phenytoin (Dilantin), Carbamazepine (Carbatrol), Divalproex Sodium (Depakote), and Ethosuximide (Zarontin).

The global anti-epileptic drugs for pediatrics market was valued at US$ 772.6 million in 2016 and is expected to witness a robust CAGR of 7.9% over the forecast period (2017-2025).

Figure 1. Global anti-epileptic drugs for pediatrics market share (%), by drug type

anti-epileptic drugs market

Source: Coherent Market Insights Analysis (2017)

Novel medications and effective drug therapy options are expected to boost the market in the forecast period

The number of available anti-epilepsy drugs has doubled over the last few decades and nine new drugs for treatment of pediatric epilepsy were launched in the last decade, as the benefits of the medicines are greater than the subsequent side-effects from the medicine. Third generation epilepsy drugs are rapidly replacing second and first generation drugs, as they are more safe and tolerable than the previous generation drugs. The newer drugs have better efficacy, with much better pharmacokinetic profiles and fewer drug interactions than the classic first generation drugs. For instance, the third generation drugs, UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) have rapidly become commonly used drugs for first-line treatments. The anticonvulsant medications are only FDA-approved for seizure disorders among children. Also, the currently available newer anti-seizure drugs have simple pharmacokinetics and more limited effects on liver metabolism, thus driving the anti-epileptic drugs for pediatrics market.

Some major players operating in the anti-epileptic drugs for pediatrics market are Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare spending and emergence of efficacious newer anti-epileptic drugs. Furthermore, co-morbidities associated with epilepsy such as depression and anxiety are on rise and major players are investing in the research and awareness programs for reduction of these co-morbidities along with epilepsy. For instance, Sanofi, S.A. invests major amounts into awareness programs in regions with emerging economies such as Latin America, Africa, and Asia Pacific. The company offers products with price adjustments in these regions to increase the access to these treatments. The investments by major players in the pipeline over the past few years have shown positive results in terms of product launches such as Vimpat drug approvals in Europe and Japan in the treatment of partial onset seizures for UCB Pharma in 2016.

Market Dynamics

Major market players are focusing on providing viable treatment options in patients suffering from refractory epilepsy or drug resistant epilepsy. The add-on or adjunctive therapies designed by market players offer significant positive results with relatively less side effects. This, in turn, is expected to boost the market growth rate for anti-epileptic drugs. Some notable drugs in the pipeline such as Lyrica (Pregabalin), are showing potential therapeutic effects with fewer drug interactions, improved side effect profiles, and enhanced overall safety. This addresses a major need in the AED market, since most of the older treatments such as carbamazepine, valproate, and phenytoin, although effective, have very poor safety profiles and are not well-tolerated by pediatric patients.

Market Taxonomy

This report segments the global Anti-Epileptic Drugs for Pediatrics Market on the basis of drug type and region. On the basis of drug type, the global Anti-Epileptic Drugs for Pediatrics Market is segmented into 1stgeneration, 2nd generation, and 3rd generation.

Key features of the study:

  • This report provides in-depth analysis of Anti-Epileptic Drugs for Pediatrics Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2016 – 2025), considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Anti-Epileptic Drugs for Pediatrics Market on the basis of the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Mylan N.V.*, Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Anti-Epileptic Drugs for Pediatrics Market report caters to various stakeholders in this industry, including investors, suppliers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Anti-Epileptic Drugs for Pediatrics Market

Detailed Segmentation:

  • Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
  • Global Anti-Epileptic Drugs for Pediatrics Market, By Geography:
    • North America
      • U.S.
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Canada
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
    • Europe
      • U.K.
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Germany
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Italy
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • France
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Russia
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Rest of Europe
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
    • Asia-Pacific
      • China
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • India
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
  • 3rd Generation
      • Japan
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • ASEAN
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Australia
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • South Korea
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Rest of Asia Pacific
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
    • Latin America
      • Brazil
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Mexico
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Rest of Latin America
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
    • Middle East
      • GCC
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Israel
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
    • Africa
      • North Africa
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • Central Africa
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
      • South Africa
        • By Drug Type:
          • 1st Generation
          • 2nd Generation
          • 3rd Generation
  • Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Mylan N.V.*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cephalon, Inc.
      • GlaxoSmithKline plc
      • Janssen Pharmaceuticals
      • Novartis AG
      • Pfizer, Inc.
      • Sanofi S.A.
      • UCB Pharma Limited
      • Sunovion Pharmaceuticals Limited
      • Valeant Pharmaceuticals International, Inc.
      • Zogenix
      • GW Pharmaceuticals
      • Insys
      • Zynerba
    • Analyst Views
  • Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025”.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
        • Supply Side Drivers
        • Demand Side Drivers
        • Economic Drivers
      • Restraints
      • Market Opportunities
      • Epidemiology
      • Merger and Acquisitions
      • PEST Analysis
      • Pipeline Drug Analysis
      • Recently Launched Drug Analysis
    • Cost Tier Down Analysis
  4. Global Anti-Epileptic Pediatric Drugs Market, By Drug Type, 2017 - 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 - 2025
      • Segment Trends
    • 1st Generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
    • 2nd Generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
    • 3rd Generation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
  5. Global Anti-Epileptic Pediatric Drugs Market, By Regions, 2017 - 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2025
    • North America
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • U.S.
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Canada
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
    • Europe
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • U.K.
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Germany
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Italy
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • France
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Russia
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Others
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • China
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • India
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Japan
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • ASEAN
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Australia
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • South Korea
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Others
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
    • Latin America
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • Brazil
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Mexico
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Others
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
    • Africa
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • Northern Africa
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Central Africa
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • South Africa
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
    • Middle East
      • Market Share Analysis, By Country, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Country, 2017 - 2025
        • GCC Countries
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Israel
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
        • Others
          • Country Trends
          • Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
  6. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Mylan N.V.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cephalon, Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline plc
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Janssen Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Novartis AG
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer, Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sanofi S.A.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • UCB Pharma Limited
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sunovion Pharmaceuticals Limited
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Valeant Pharmaceuticals International, Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zogenix
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GW Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Insys
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zynerba
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      •  
    • Analyst Views
  7. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.